Market Intelligence, Preclinical Progress, and High-Purity Reagents for Anti-Apoptotic & Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for API5 (Apoptosis Inhibitor 5 / AAC-11) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | API5 Full-Length & Truncated Recombinant Protein High purity (>95%), Endotoxin < 1 EU/μg. Sequence Verified. HEK293 or E. coli expressed. |
View API5 Products |
| Gene Delivery | API5 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Native codon optimization. Lentivirus particles (≥1×10⁸ TU/mL). |
View API5 Products |
| Benchmark Ab | Anti-API5 Recombinant Antibody Research-grade binder for IHC, Flow cytometry, Western blot, co-IP, and target engagement studies. |
View API5 Products |
| Validator | API5 siRNA Set (3 pre-designed sequences) For knockdown verification and assay specificity controls. >75% knockdown efficiency. |
View API5 Products |
| Related Target A | ACIN1 (Acinus) Direct PPI partner of API5; essential for apoptotic chromatin condensation assays. |
View ACIN1 Products |
| Related Target B | CASP3 (Caspase-3) Downstream executioner caspase; apoptotic readout for API5 pathway modulation. |
View CASP3 Products |
| Related Target C | BCL2 Parallel anti-apoptotic pathway; synergistic survival mechanism analysis. |
View BCL2 Products |
| Related Target D | FGF2 Crucial interacting partner for API5-mediated tumor survival. |
View FGF2 Products |
| Related Target E | E2F1 Transcription factor whose apoptotic signaling is inhibited by API5. |
View E2F1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular PPI Disruption (API5–ACIN1 interface) | Full-length & domain-truncated API5 proteins, >95% purity, Endotoxin < 1 EU/μg; sequence verified by mass spec for pull-down / AlphaScreen / SPR. |
| Nuclear Localization & Cell Engagement | API5 Lentivirus Premade Particles for stable HEK293 cell line construction; preserves native conformation for flow cytometry & immunofluorescence. |
| Specificity Controls for RNAi | Validated siRNA set with >75% knockdown efficiency; eliminates false positives from off-target apoptosis modulators. |
| Cross-species Preclinical Translation | Human/Mouse/Rat ortholog proteins available with >95% purity for xenograft model validation. |
| Target Validation & False Positives | Sequence-verified Benchmark Antibodies and siRNA included for definitive specificity and phenotypic rescue checks. |
Live API5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
API5 (Apoptosis Inhibitor 5, AAC-11) is a nuclear anti-apoptotic scaffold protein that suppresses programmed cell death by sequestering ACIN1 and blocking E2F1-induced apoptosis. It also interacts with FGF2 to stabilize tumor survival signaling. Overexpression in solid tumors (lung, breast, cervical, ovarian) correlates with chemoresistance and poor prognosis, positioning API5 as an emerging target for oncology drug discovery. The current pipeline remains predominantly preclinical, with first-generation siRNA and small molecule inhibitors entering IND-enabling studies. Therapeutic strategies pivot toward peptide-based PPI disruptors, cell-penetrating biologics, gene silencing, and PROTACs. As the field advances, R&D is expected to focus on nuclear entry optimization, combination regimens with DNA-damaging agents, and selective ACIN1 interface inhibitors, while monitoring parallel anti-apoptotic pathways (BCL2, MCL-1) for resistance compensation.
Competitive Modality & Indication Snapshot
| Modality | Representative Approach / Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Peptide Mimetic / Stapled Peptide | Academic & Early Biotech | Solid Tumors (Lung, Breast, Cervical) | PPI Competition Assay (Need high-purity API5 & ACIN1 proteins) |
| Small Molecule PPI Inhibitor | Structure-based Drug Design; Early-stage Biotech | Refractory / Metastatic Cancers, Hematologic Malignancies | Thermal Shift & SPR (Need stable, full-length API5) |
| siRNA / Antisense Oligonucleotide | Academic Consortiums, Gene Silencing Platforms | Chemoresistant Tumors, Ovarian Cancer | Knockdown Efficiency & Apoptosis Readout (Need API5 siRNA + CASP3 assays) |
| PROTACs | Emerging Innovators | Chemoresistant Solid Tumors | Degradation Assays (Need API5 Lentivirus for stable cell lines and full-length protein for ternary complex formation) |